Related Experiment Video
Updated: Sep 14, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
The effect and related mechanisms of RAC1 GTP on radiotherapy for hepatocellular carcinoma
Xiaoyu Xu1, Zhengxuying Fang1, Wei Jiang1
11Department of Oncology, The Yuyao People's Hospital, Ningbo, China; 2Department of Health Science Center, Medical College of Ningbo University, Ningbo, China; 3Department of Oncology, The Ningbo 7th People's Hospital, Ningbo, China; 4Department of Radiation Oncology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
Background:
Ras-related C3 botulinum toxin substrate 1 (RAC1), a pivotal Rho guanosine triphosphatases (GTPase) implicated in oncogenic processes and radiotherapeutic resistance across malignancies, has not been extensively examined within the context of hepatocellular carcinoma (HCC) radiotherapy. Therefore, this study aimed to evaluate the expression and prognostic significance of RAC1 in HCC, investigate the molecular mechanisms by which radiation-induced RAC1 GTPase activity mediates radioresistance, and validate targeted inhibition of this activity as a potential strategy to enhance HCC radiosensitivity.
Methods:
RAC1 expression was assessed in HCC versus adjacent tissues via The Cancer Genome Atlas (TCGA) and immunohistochemical (IHC) staining of clinical specimens. Its prognostic significance was rigorously evaluated using Cox regression models and visualized via nomogram construction. Radiation-induced RAC1 GTP activity in MHCC97-H cells was quantified by G-protein-linked immunosorbent assay (G-LISA), with downstream signaling (p-IκBα/Bcl-xL) and cell cycle dynamics analyzed via Western blotting and flow cytometry. NSC23766, a RAC1 GTP inhibitor, was employed to identify the pathway-specific effects.
Results:
RAC1 exhibited marked overexpression in HCC tissues, correlating with advanced pathological stages and inferior prognosis. Radiation triggered RAC1 GTP activation in MHCC97-H cells, driving p-IκBα/Bcl-xL antiapoptotic signaling and G2/M arrest. NSC23766 suppressed radiation-induced IκBα phosphorylation (P<0.05), Bcl-xL upregulation, and cell cycle arrest attenuating radioresistance.
Conclusions:
RAC1 overexpression portends poor HCC prognosis and mediates radioresistance through GTP-dependent activation of antiapoptotic pathways and cell cycle modulation. Targeting RAC1 GTP activity may enhance the radiosensitivity of HCC.
Insights
Ras-related C3 botulinum toxin substrate 1 (RAC1) is overexpressed in hepatocellular carcinoma (HCC), driving radioresistance. Inhibiting RAC1 GTPase activity may improve HCC radiotherapy outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy Research
Background:
- Ras-related C3 botulinum toxin substrate 1 (RAC1) is a Rho GTPase involved in cancer progression and treatment resistance.
- RAC1's role in hepatocellular carcinoma (HCC) radiotherapy has not been thoroughly investigated.
- Understanding RAC1's function in HCC is crucial for improving radiotherapy efficacy.
Purpose of the Study:
- To evaluate RAC1 expression and its prognostic value in HCC.
- To elucidate the mechanisms of radiation-induced RAC1 GTPase activity in radioresistance.
- To validate RAC1 inhibition as a strategy to enhance HCC radiosensitivity.
Main Methods:
- Assessed RAC1 expression in HCC tissues using TCGA and immunohistochemistry.
- Evaluated prognostic significance with Cox regression and nomogram construction.
- Quantified radiation-induced RAC1 GTP activity and analyzed downstream signaling (p-IκBα/Bcl-xL) and cell cycle dynamics.
- Utilized NSC23766, a RAC1 inhibitor, to assess pathway-specific effects.
Main Results:
- RAC1 was significantly overexpressed in HCC, correlating with advanced stages and poor prognosis.
- Radiation activated RAC1 GTPase in HCC cells, promoting antiapoptotic signaling (p-IκBα/Bcl-xL) and G2/M cell cycle arrest.
- NSC23766 treatment inhibited radiation-induced IκBα phosphorylation, Bcl-xL upregulation, and cell cycle arrest, thereby reducing radioresistance.
Conclusions:
- Overexpression of RAC1 in HCC predicts a poor prognosis and contributes to radioresistance via GTP-dependent activation of antiapoptotic pathways and cell cycle modulation.
- Targeting RAC1 GTPase activity presents a promising therapeutic strategy to enhance HCC radiosensitivity.
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a...
Directionality of Nuclear Transport
Intracellular Signaling Affects Focal Adhesions
Some...
GTPases and their Regulation
Large G-proteins,...
Activation and Inactivation of G Proteins

